Phase IIB Dose Ranging Study of BMS-945429 in subjects with moderate to severe Crohn’s Disease

Mise à jour : Il y a 5 ans
Référence : EUCTR2011-004763-72

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to characterize the safety, efficacy and dose response of BMS-945429 in subjects with moderate to severe Crohn’s disease and who have had an insufficient response to conventional therapy or have failed anti-TNF therapy


Critère d'inclusion

  • Crohn’s Disease